In the SURPASS clinical trial program for type 2 diabetes, patients achieved HbA1c reductions of 1.9% to 2.6% depending on dose, with weight loss averaging 15-22 pounds across studies
The 2-minute half-life cited in the body of this article is what survives that first pass
doi: 10.1210/jendso/bvad114.108
Thats why oral peptide GLP1s typically need protective formulations and absorption strategies, plus clear timing rules (food can reduce absorption)
*Correspondence: Jens Juul Holst [email protected] This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The FDA has also said some companies are mass-marketing non-FDA-approved compounded GLP-1s as alternatives to approved drugs, and the agency is moving to restrict these practices as supply stabilizes